IceCure 9M 2026: Revenue Up 26% to $2.6M, U.S. Sales +83%, Cash Down to $8.2M
ICCM sits 43% above its 52-week low of $0.65.
Summary
IceCure reported 9M 2026 revenue of $2.6M, up 26% year over year, with U.S. sales up 83% and commercial reach at 21 states. The net loss widened to $13.0M and cash stood at $8.2M on September 30, 2026.
Key Events · Earnings and Guidance · ICCM
-
9M Revenue Grows 26% to $2.6M
Total revenues were $2.642M for the nine months ended September 30, 2026, versus $2.100M a year earlier, with U.S. ProSense and cryoprobe sales up 83% year over year.
-
Loss Widens, Cash Falls to $8.2M
Net loss was $12.995M versus $10.811M, and operating cash burn was $12.575M. Cash and equivalents ended at $8.220M, down from $8.897M at December 31, 2025.
-
Share Count More Than Doubled
Issued and outstanding shares rose to 5,563,265 at September 30, 2026 from 2,437,410 at December 31, 2025, after $12.020M of net equity proceeds in the period.
-
Reverse Split Vote Set for November 19
Shareholders are being asked at the November 19, 2026 meeting to authorize one or more reverse splits of 5-for-1 up to 15-for-1, a vote that falls one day after this release.
Analysis · ICCM · Industrial Applications And Services
Revenue growth is real but small in absolute terms — $2.6M over nine months against a $13.0M net loss. The gap is what matters: cash fell to $8.2M from $8.9M at year-end, and the company burned $12.6M on operations in nine months, so the balance sheet covers roughly six months of that burn without new money. IceCure has been funding itself through equity — $12.0M raised in the period and share count up from 2.44M to 5.56M — and a shareholder vote on a reverse split of 5-for-1 up to 15-for-1 is scheduled for the November 19, 2026 meeting, one day after this release. The 83% U.S. sales jump and expansion from 11 to 21 states are the operating bright spot, but the reimbursement setback (AMA declined a permanent CPT Category I code in October) still caps how fast that converts into revenue.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ICCM was trading at $0.93 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.8M. The 52-week trading range was $0.65 to $22.50. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.